FDA-EMA work­shop dis­cuss­es qual­i­ty chal­lenges for PRIME, break­through ther­a­pies

Last No­vem­ber, of­fi­cials from the EMA and FDA met with in­dus­try rep­re­sen­ta­tives in Lon­don to dis­cuss the var­i­ous qual­i­ty chal­lenges that arise when the de­vel­op­ment of in­ves­ti­ga­tion­al prod­ucts is ac­cel­er­at­ed.

The EMA’s launch of its pri­or­i­ty med­i­cines (PRIME) scheme and the FDA’s break­through ther­a­py des­ig­na­tion have en­abled com­pa­nies to speed cer­tain treat­ments to mar­ket, al­though there have been dif­fi­cul­ties in iden­ti­fy­ing pos­si­ble sci­en­tif­ic and reg­u­la­to­ry ap­proach­es to fa­cil­i­tate the type of ro­bust qual­i­ty da­ta pack­ages nec­es­sary to en­sure that pa­tient safe­ty and prod­uct qual­i­ty and ef­fi­ca­cy are not com­pro­mised, ac­cord­ing to a re­port re­leased Wednes­day on the work­shop.

Ramesh Sood

In ad­di­tion to the fo­cus on ear­ly ac­cess ap­proach­es, the work­shop dis­cussed process val­i­da­tion, con­trol strate­gies, good man­u­fac­tur­ing prac­tice (GMP) com­pli­ance, com­pa­ra­bil­i­ty, sta­bil­i­ty and reg­u­la­to­ry tools.

Ramesh Sood, se­nior sci­en­tif­ic ad­vi­sor at the FDA’s Of­fice of New Drugs, dis­cussed the agency’s break­through pro­gram, not­ing the chal­lenges faced by ap­pli­cants col­lect­ing the nec­es­sary man­u­fac­tur­ing da­ta and pro­vid­ing an ad­e­quate man­u­fac­tur­ing con­trol strat­e­gy.

“It be­comes im­por­tant for the Agency re­view­ers to do a risk-ben­e­fit as­sess­ment re­gard­ing [the] risk of less man­u­fac­tur­ing in­for­ma­tion ver­sus pa­tient ben­e­fit,” the work­shop re­port says of Sood’s pre­sen­ta­tion. “This re­quires in­no­v­a­tive risk-mit­i­ga­tion strate­gies to en­sure prod­uct qual­i­ty and re­duce the qual­i­ty-re­lat­ed prod­uct risk to an ac­cept­able lev­el.”

Veroni­ka Jek­er­le

Veroni­ka Jek­er­le of the EMA’s qual­i­ty of­fice al­so dis­cussed the sci­en­tif­ic chal­lenges for PRIME can­di­dates, which in­clude ab­bre­vi­at­ed time­lines that add con­straints to set­ting up com­mer­cial man­u­fac­tur­ing sites.

“An analy­sis ex­am­in­ing sci­en­tif­ic is­sues most com­mon­ly iden­ti­fied by PRIME ap­pli­cants (as in­di­cat­ed by SA [sci­en­tif­ic ad­vice] re­quests) re­vealed the fol­low­ing ar­eas as the most crit­i­cal: start­ing ma­te­ri­als, com­pa­ra­bil­i­ty, process val­i­da­tion, an­a­lyt­i­cal con­trol strat­e­gy, spec­i­fi­ca­tions and sta­bil­i­ty,” the re­port says.

Stu­art Finnie, di­rec­tor of reg­u­la­to­ry CMC at As­traZeneca, al­so pre­sent­ed on a small mol­e­cule prod­uct that earned the FDA’s break­through des­ig­na­tion but ran in­to process val­i­da­tion prob­lems that meant sup­plies of the drug would come four months af­ter ap­proval.

As­traZeneca ap­proached the FDA and dis­cussed de­cou­pling the val­i­da­tion of drug sub­stance and drug prod­uct, and dis­cussed plans to use drug sub­stance man­u­fac­tured in the clin­i­cal fa­cil­i­ty to sup­ply drug prod­uct val­i­da­tion.

“Three key el­e­ments lead to the suc­cess of this pro­pos­al,” the re­port says of the As­traZeneca work. “First­ly, the ap­pli­cant pro­vid­ed the Agency with sig­nif­i­cant ev­i­dence of sim­i­lar­i­ty in terms of qual­i­ty, man­u­fac­tur­ing process and qual­i­ty sys­tem be­tween the clin­i­cal cam­paigns and the pro­posed com­mer­cial cam­paign. Sec­ond­ly, dur­ing the site in­spec­tion there was open and close en­gage­ment be­tween the in­spec­tors, re­view­ers, sub­ject mat­ter ex­perts and qual­i­ty de­part­ments en­sur­ing that ques­tions raised were an­swered swift­ly lead­ing to a bal­anced and aligned view on risk as­sess­ment. Fi­nal­ly, and most im­por­tant­ly, it was clear that through­out the in­ter­ac­tions all par­ties were fo­cused on en­sur­ing sup­ply to the pa­tient.”

Oth­er in­dus­try pre­sen­ta­tions in­volved rep­re­sen­ta­tives from Pfiz­er, Am­gen, Cel­gene, MSD (known as Mer­ck in the US), Bio­gen and sev­er­al vac­cine man­u­fac­tur­ers, among oth­ers.

As far as fu­ture joint EMA-FDA ac­tions, the re­port points to the use of mod­els for sta­bil­i­ty and shelf life de­ter­mi­na­tions, in­no­v­a­tive process val­i­da­tion ap­proach­es and al­low­ing launch­es from clin­i­cal man­u­fac­tur­ing sites.

Ned Sharp­less NIH

“In ad­di­tion, the or­ga­niz­ing com­mit­tee pro­pos­es to de­vel­op a ‘Tool­box- guid­ance’ for PRIME prod­ucts, which shall sum­marise the iden­ti­fied sci­en­tif­ic el­e­ments/reg­u­la­to­ry tools that are al­ready avail­able in the EU to ad­dress some of the chal­lenges faced dur­ing the de­vel­op­ment of prod­ucts un­der PRIME and gen­er­a­tion of ro­bust qual­i­ty pack­ages for MAA [mar­ket­ing au­tho­riza­tion ap­pli­ca­tion] re­view,” the re­port says.

Act­ing FDA Com­mis­sion­er Ned Sharp­less added in a state­ment: “We will con­tin­ue to work with our EMA col­leagues and in­dus­try to dis­cuss ways to ad­dress qual­i­ty chal­lenges as­so­ci­at­ed with ex­pe­dit­ed de­vel­op­ment pro­grams to help en­sure pa­tients re­ceive safe, ef­fec­tive drugs.”

Work­shop Re­port

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.


Zachary Brennan

managing editor, RAPS

Mer­ck is tak­ing the ax to its US op­er­a­tions, cut­ting 500 jobs in its lat­est re­or­ga­ni­za­tion

Merck is cutting 500 jobs in its US sales and headquarters commercial teams in its latest effort to find new ways to streamline the operation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Alice Shaw, Lung Cancer Foundation of America

Top ALK ex­pert and can­cer drug re­searcher Al­ice Shaw bids adieu to acad­e­mia, hel­lo to No­var­tis

Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

Flu Virus (Source: CDC)

FDA ex­pands Xofluza ap­proval as Roche strug­gles to catch loom­ing flu mar­ket

As a potentially powerful flu season looms, so does a big test for Roche and its new flu drug, Xofluza. The Swiss giant just got a small boost in advance of that test as the FDA expanded Xofluza’s indication to include patients at high risk of developing flu-related complications.

Xofluza (baloxavir marboxil) was approved last October in the US, the first landmark flu drug approval in 20 years and a much-needed green light for a company that had watched its leading flu drug Tamiflu get eaten alive by generics. Like its predecessor, the pill offered a reduction in flu symptoms but not a cure.

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

The first-ever Ebola vaccine is on the precipice of approval after the European Medicine’s Agency (EMA) backed the Merck product in this week’s roster of recommendations.

The drugmaker $MRK began developing the vaccine, christened Ervebo, during the West African outbreak that occurred between 2014 and 2016, killing more than 11,000.

The current outbreak in the Democratic Republic of Congo (DRC) has shown case fatality rates of approximately 67%, the agency estimated. Earlier this year, the WHO declared the outbreak — which so far has infected more than 3,000 people — a public health emergency of international concern.

Ronald Herb­st fol­lows Med­Im­mune ex­o­dus to Pyx­is CSO post; Jeff God­dard to suc­ceed CEO of AIT Bio­science

→ The outflow of top execs from MedImmune continues to fill the leadership ranks of smaller biotechs. The latest to take off is Ronald Herbst, the head of oncology research, who’s assuming the CSO post at Pyxis Oncology.  

Herbst was part of the old MedImmune organization AstraZeneca CEO Pascal Soriot restructured earlier this year, reorganizing the company and eliminating the storied subsidiary as a separate organization.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: J&J's Xarel­to, Amar­in's Vas­cepa are cost-ef­fec­tive, not bud­get friend­ly — ICER

ICER, an increasingly influential cost-effectiveness watchdog in the United States, has concluded in its review of treatments for cardiovascular disease that while the cost of J&J’s Xarelto and Amarin’s Vascepa meet its benchmark for value pricing — the two treatments will not likely treat as many patients as hoped without surpassing the annual budget threshold calculated by ICER for each therapy.

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT.

That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Mirati has been experiencing the full effect of a rival’s initial success at targeting the G12C pocket found on KRAS, offering the biotech some support on the concept they’re after — and biotech fans a race to the top. Amgen made a big splash with its first positive snapshot on lung cancer, but deflated sky-high expectations as it proved harder to find similar benefits in other types of cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.